logo
Bioanalysis special focus issue on antibody–drug conjugates
Insights into antibody–drug conjugates: bioanalysis and biomeasures in discovery
Key bioanalytical measurements for antibody–drug conjugate development: PK/PD modelers’ perspective
NanoString® launches its first commercial diagnostic product
Partnership announced at Pittcon 2013
Oxford Gene Technology signs license agreement with Cancer Cytogenomics Microarray Consortium
Xceleron and JCL Bioassay form early-phase clinical trial partnership
John Hopkins University strikes deal with Advanced Cell Diagnostics
Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper
Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
PK assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates
Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum
Novel detection of DNA-alkylated adducts of antibody–drug conjugates with potentially unique preclinical and biomarker applications
A personal perspective of the development and validation of a phase-specific antibody–drug conjugate cytotoxicity potency assay
Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy
Strategies to address drug interaction potential for antibody–drug conjugates in clinical development
A novel approach to capillary plasma microsampling for quantitative bioanalysis
Acknowledgements